Volume 24, Issue 4 (7-2020)                   IBJ 2020, 24(4): 229-235 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rezaie R, Falakian Z, Mazloomzadeh S, Ayati M, Morakabati A, Teimouri Dastjerdan M R, et al . While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value. IBJ 2020; 24 (4) :229-235
URL: http://ibj.pasteur.ac.ir/article-1-3101-en.html
Background: Numerous studies confirmed that significant decrease in tissue decorin (DCN) expression is associated to tumor progression and metastasis in certain types of cancer including prostate cancer (PC). However, the potential prognostic value of tissue DCN in PC has not yet been investigated. Methods: A total number of 40 PC and 42 patients with benign prostatic hyperplasia (BPH) were investigated for the expression levels of DCN in their prostatic tissues using real-time quantitative polymerase chain reaction and immunohistochemical analyses. Urinary and plasma DCN levels were also measured by ELISA. Results: Despite no significant changes in the mean of urine and plasma DCN concentrations between the two study groups, tissue DCN mRNA was found to be 5.5fold lower in cancer than BPH (p = 0.0001). Similarly, the stained DCN levels appeared significantly lower in cancer patients with higher Gleason Scores (8 and 9, n = 6) than those with lower Gleason Scores (6 and 7, n = 26), with a p value of 0.049. Conclusion: Here, we report, for the first time, that urine and plasma DCN does not seem to have a diagnostic value in PC, while tissue DCN could potentially be used as a prognostic marker in PC.
Type of Study: Full Length/Original Article | Subject: Related Fields

1. Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate cancer and prostatic diseases 2017; 20(1): 12-19. [DOI:10.1038/pcan.2016.59]
2. Yu Q, Xin K, Miao Y, Li Z, Fu S, Hu S, Zhang Q, Zhou S. Anti-tumor responses to hypofractionated radiation in mice grafted with triple negative breast cancer is associated with decorin induction in peritumoral muscles. Acta biochimica et biophysica sinica 2018; 50(11): 1150-1157. [DOI:10.1093/abbs/gmy094]
3. Edwards IJ. Proteoglycans in prostate cancer. Nature reviews urology 2012; 9(4): 196-206. [DOI:10.1038/nrurol.2012.19]
4. Sofeu Feugaing DD, Gotte M, Viola M. More than matrix: the multifaceted role of decorin in cancer. European journal of cell biology 2013; 92(1): 1-11. [DOI:10.1016/j.ejcb.2012.08.004]
5. Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L, Iozzo RV. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. The journal of biological chemistry 2012; 287(8): 5492-5506. [DOI:10.1074/jbc.M111.283499]
6. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, Iozzo RV. Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. The journal of biological chemistry 2010; 285(53): 42075-42085. [DOI:10.1074/jbc.M110.172841]
7. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, Gomella LG, Owens RC, Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. The journal of biological chemistry 2011; 286(40): 34712-34721. [DOI:10.1074/jbc.M111.262766]
8. Baghy K, Dezso K, Laszlo V, Fullar A, Peterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV, Kovalszky I. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Laboratory investigation 2011; 91(3): 439-451. [DOI:10.1038/labinvest.2010.172]
9. Vial C, Gutierrez J, Santander C, Cabrera D, Brandan E. Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. The journal of biological chemistry 2011; 286(27): 24242-24252. [DOI:10.1074/jbc.M110.189365]
10. Buraschi S, Neill T, Goyal A, Poluzzi C, Smythies J, Owens RT, Schaefer L, Torres A, Iozzo RV. Decorin causes autophagy in endothelial cells via Peg3. Proceedings of the national academy of sciences of the United States of America 2013; 110(28): E2582-2591. [DOI:10.1073/pnas.1305732110]
11. Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix. American journal of pathology 2012; 181(2): 380-387. [DOI:10.1016/j.ajpath.2012.04.029]
12. Li SJ, Chen DL, Zhang WB, Shen C, Che GW. Prognostic value of stromal decorin expression in patients with breast cancer: a meta-analysis. Journal of thoracic disease 2015; 7(11): 1939-1950.
13. Appunni S, Anand V, Khandelwal M, Seth A, Mathur S, Sharma A. Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial
14. carcinoma of bladder. Tumour biology 2017; 39(5): 1010428317699112.
15. Hong X, Yang Z, Wang M, Wang L, Xu Q. Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I-IIIA non-small cell lung cancer. Tumour biology 2016; Epub ahead of print] reterieved from: https://www.ncbi.nlm.nih.gov/pubmed/27726099. [DOI:10.1007/s13277-016-5431-1]
16. Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Nepomnyashchikh GI, Aidagulova SV, Grigorieva EV. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN oncologyl 2013: 680136. [DOI:10.1155/2013/680136]
17. Wu IC, Wu DC, Huang CC, Lin HS, Chen YK, Tsai HJ, Lu CY, Chou SH, Chou YP, Li LH, Tai SY, Wu MT. Plasma decorin predicts the presence of esophageal squamous cell carcinoma. International journal of cancer 2010; 127(9): 2138-2146. [DOI:10.1002/ijc.25239]
18. Falakian Z, Shahani T, Rezaei R, Mazloomzadeh S, Sirati F, Jalilvand A, Bahmani P, Biglari A,Jadali F,Atarian S, Eghdam-Zamir R. Patients with Invasive ductal Carcinoma have reduced levels of decorin expression in their breast tissue of compared of patients with fibroadenoma while their plasma decorin remains unchanged. Archive of iranian medicine 2018; 21(11): 509-517.
19. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A. Quantitative multi-gene expression profiling of primary prostate cancer. The prostate 2006; 66(14): 1521-1534. [DOI:10.1002/pros.20490]
20. Tsaur I, Renninger M, Hennenlotter J, Oppermann E, Munz M, Kuehs U, Stenzl A, Schilling D. Reliable housekeeping gene combination for quantitative PCR of lymph nodes in patients with prostate cancer. Anticancer research 2013; 33(12):5243-5248.
21. Banerjee AG, Bhattacharyya I, Lydiatt WM, Vishwanatha JK. Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma. Cancer research 2003; 63(22): 7769-7776.
22. Henke A, Grace OC, Ashley GR, Stewart GD, Riddick AC, Yeun H, O'Donnell M, Anderson RA, Thomson AA. Stromal expression of decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer. PLoS one 2012; 7(8): e42516. [DOI:10.1371/journal.pone.0042516]
23. Coulson-Thomas VJ, Gesteira TF, Coulson-Thomas YM, Vicente CM, Tersariol IL, Nader HB, Toma L. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-beta, and extracellular matrix down-regulation. Experimental cell research 2010; 316(19): 3207-3226. [DOI:10.1016/j.yexcr.2010.08.005]
24. Oda G, Sato T, Ishikawa T, Kawachi H, Nakagawa T, Kuwayama T, Ishiguro M, Iida S, Uetake H, Sugihara K. Significance of stromal decorin expression during the progression of breast cancer. Oncology reports 2012; 28(6): 2003-2008. [DOI:10.3892/or.2012.2040]
25. Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC, Roughley PJ, Watson PH. Lumican and decorin are differentially expressed in human breast carcinoma. The journal of pathology 2000; 192(3): 313-320. https://doi.org/10.1002/1096-9896(200011)192:3<313::AID-PATH694>3.0.CO;2-B [DOI:10.1002/1096-9896(200011)192:33.0.CO;2-B]
26. Sainio A, Nyman M, Lund R, Vuorikoski S, Bostrom P, Laato M, Bostrom PJ, Jarvelainen H. Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies. PLoS one 2013; 8(10):e76190. [DOI:10.1371/journal.pone.0076190]
27. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clinical cancer research 1998; 4(4): 963-971.
28. El Behi M, Krumeich S, Lodillinsky C, Kamoun A, Tibaldi L, Sugano G, De Reynies A, Chapeaublanc E, Laplanche A, Lebret T, Allory Y, Radvanyi F, Lantz O, Eijan AM, Bernard-Pierrot I, Thery C. An essential role for decorin in bladder cancer invasiveness. EMBO molecular medicine 2013; 5(12): 1835-1851 [DOI:10.1002/emmm.201302655]
29. Koninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Buchler MW, Friess H. Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clinical cancer research 2004; 10(14): 4776-4783. [DOI:10.1158/1078-0432.CCR-1190-03]
30. Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, van Oort IM, Mulders PF, Schalken JA. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clinical chemistry and laboratory medicine 2016; 54(3): 483-492. [DOI:10.1515/cclm-2015-0599]
31. Dugan TA, Yang VW, McQuillan DJ, Hook M. Decorin modulates fibrin assembly and structure. The journal of biological chemistry 2006; 281(50): 38208-38216. [DOI:10.1074/jbc.M607244200]
32. Dugan TA, Yang VW, McQuillan DJ, Hook M. Decorin binds fibrinogen in a Zn2+-dependent interaction. The journal of biological chemistry 2003; 278(16): 13655-13662. [DOI:10.1074/jbc.M300171200]
33. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clinical cancer research 2003; 9(1): 207-214.
34. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V, Guidos CJ, Vallis KA, Evans KR, McCready D, Leong WL, Done SJ. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. PLoS One 2012; 7(2): e30992. [DOI:10.1371/journal.pone.0030992]
35. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F. Insignificant prostate cancer and active surveillance: From definition to clinical implications. European urology 2009; 55(6): 1321-1331. [DOI:10.1016/j.eururo.2009.02.028]
36. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. Acontemporary analysis 2004; 101(9): 2001-2005. [DOI:10.1002/cncr.20586]

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb